| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Endocrinology and Metabolism (K.H., H.d.W., M.M.S., F.A.-R., F.S.H., P.A.H.), Department of Medicine, University of Stellenbosch, Stellenbosch 7505, South Africa; Forschungszentrum Karlsruhe (A.C.B.C.), Institute of Toxicology and Genetics, D-76021 Karlsruhe, Germany; Department of Nephrology (J.C.), The Royal Free and University College Medical School, London NW3 2PF, United Kingdom; and Department of Endocrinology (J.M.B.), St. Barts Hospital, University of London, London EC1A 7BE, United Kingdom
Address all correspondence and requests for reprints to: Dr. P. A. Hulley, Botnar Research Centre, Institute of Musculoskeletal Sciences, University of Oxford, Nuffield Orthopaedic Centre, Oxford OX3 7LD, United Kingdom. E-mail: philippa.hulley{at}ndos.ox.ac.uk.
Steroid-induced osteoporosis is a common side effect of long-term treatment with glucocorticoid (GC) drugs. GCs have multiple systemic effects that may influence bone metabolism but also directly affect osteoblasts by decreasing proliferation. This may be beneficial at low concentrations, enhancing differentiation. However, high-dose treatment produces a severe deficit in the proliferative osteoblastic compartment. We provide causal evidence that this effect of GC is mediated by induction of the dual-specificity MAPK phosphatase, MKP-1/DUSP1. Excessive MKP-1 production is both necessary and sufficient to account for the impaired osteoblastic response to mitogens. Overexpression of MKP-1 after either GC treatment or transfection ablates the mitogenic response in osteoblasts. Knockdown of MKP-1 using either immunodepletion of MKP-1 before in vitro dephosphorylation assay or short interference RNA transfection prevents inactivation of ERK by GCs. Neither c-jun N-terminal kinase nor p38 MAPK is activated by the mitogenic cocktail in 20% fetal calf serum, but their activation by a DNA-damaging agent (UV irradiation) was inhibited by either GC treatment or overexpression of MKP-1, indicating regulation of all three MAPKs by MKP-1 in osteoblasts. However, an inhibitor of the MAPK/ERK kinase-ERK pathway inhibited osteoblast proliferation whereas inhibitors of c-jun N-terminal kinase or p38 MAPK had no effect, suggesting that ERK is the MAPK that controls osteoblast proliferation. Regulation of ERK by MKP-1 provides a novel mechanism for control of osteoblast proliferation by GCs.
NURSA Molecule Pages Link:
This article has been cited by other articles:
 |
|
 |
|
  A. Chiloeches, A. Sanchez-Pacheco, B. Gil-Araujo, A. Aranda, and M. Lasa Thyroid Hormone-Mediated Activation of the ERK/Dual Specificity Phosphatase 1 Pathway Augments the Apoptosis of GH4C1 Cells by Down-Regulating Nuclear Factor-{kappa}B Activity Mol. Endocrinol., November 1, 2008; 22(11): 2466 - 2480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Johansson-Haque, E. Palanichamy, and S. Okret Stimulation of MAPK-phosphatase 1 gene expression by glucocorticoids occurs through a tethering mechanism involving C/EBP J. Mol. Endocrinol., October 1, 2008; 41(4): 239 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Clark, J. R. S. Martins, and C. R. Tchen Role of Dual Specificity Phosphatases in Biological Responses to Glucocorticoids J. Biol. Chem., September 19, 2008; 283(38): 25765 - 25769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Diefenbacher, S. Sekula, C. Heilbock, J. V. Maier, M. Litfin, H. van Dam, M. Castellazzi, P. Herrlich, and O. Kassel Restriction to Fos Family Members of Trip6-Dependent Coactivation and Glucocorticoid Receptor-Dependent Trans-Repression of Activator Protein-1 Mol. Endocrinol., August 1, 2008; 22(8): 1767 - 1780. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
